S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

$32.97
-0.81 (-2.40 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
$32.57
Now: $32.97
$34.50
50-Day Range
$25.19
MA: $29.80
$33.75
52-Week Range
$15.17
Now: $32.97
$34.49
Volume112,848 shs
Average Volume150,524 shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.11 per share

Profitability

Net Income$-43,270,000.00

Miscellaneous

Employees32
Market Cap$1.31 billion
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its earnings results on Wednesday, November, 13th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

What price target have analysts set for YMAB?

4 Wall Street analysts have issued 1-year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $40.00. On average, they expect Y-mAbs Therapeutics' share price to reach $39.33 in the next year. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

What is the consensus analysts' recommendation for Y-mAbs Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

Media stories about YMAB stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Y-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,080,000 shares, an increase of 29.4% from the October 31st total of 834,400 shares. Based on an average daily trading volume, of 200,200 shares, the short-interest ratio is currently 5.4 days. Currently, 7.6% of the company's stock are short sold. View Y-mAbs Therapeutics' Current Options Chain.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the folowing people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (0.89%), Millennium Management LLC (0.47%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.12%), California State Teachers Retirement System (0.08%) and Strs Ohio (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

Which institutional investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Strs Ohio, Tuttle Tactical Management, California Public Employees Retirement System, Metropolitan Life Insurance Co NY, Rhumbline Advisers and California State Teachers Retirement System. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $32.97.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.31 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


MarketBeat Community Rating for Y-mAbs Therapeutics (NASDAQ YMAB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote "Outperform" if you believe YMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: Market Capitalization

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel